• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

    21.72 +0.15 (+0.70%)
    Streaming Delayed Price Updated: 1:56 PM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 624,447
    Open 21.13
    Bid (Size) 21.71 (200)
    Ask (Size) 21.73 (500)
    Prev. Close 21.57
    Today's Range 21.00 - 21.84
    52wk Range 12.72 - 31.77
    Shares Outstanding 50,241,789
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Arcutis (ARQT) Q1 2026 Earnings Transcript ↗
    Arcutis (ARQT) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide ↗
    Via Chartmill

    Performance

    YTD
    -25.1%
    -25.1%
    1 Month
    -13.4%
    -13.4%
    3 Month
    -18.7%
    -18.7%
    6 Month
    -5.0%
    -5.0%
    1 Year
    +59.7%
    +59.7%

    More News

    Read More
    News headline image
    Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Surpasses Q4 Estimates and Raises 2026 Sales Outlook ↗
    Via Chartmill
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows Technical Breakout Setup ↗
    Via Chartmill
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows High-Growth Momentum and Strong Technical Setup ↗
    Via Chartmill
    News headline image
    Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate ↗
    Via Chartmill
    News headline image
    Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis (ARQT) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit ↗
    Via The Motley Fool
    News headline image
    Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics (NASDAQ:ARQT) Combines High-Growth Momentum with Bullish Technical Setup ↗
    Via Chartmill

    Frequently Asked Questions

    Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?
    Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.
    What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?
    Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?
    The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market
    What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?
    The current price of Arcutis Biotherapeutics, Inc. - Common stock is 21.72
    When was Arcutis Biotherapeutics, Inc. - Common stock last traded?
    The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 05/15/26 01:56 PM ET
    What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?
    The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.09B
    How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?
    Arcutis Biotherapeutics, Inc. - Common stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.